<h4>Background</h4>The benefit of first-line use of sodium-dependent glucose transport 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in type 2 diabetes mellitus (T2DM) with low risk of cardiovascular diseases are not clear.<h4>Methods</h4>PubMed, EMBASE and Cochrane Library databases were searched to identify eligible randomized controlled trials. The gene discussed is GLP1R; the disease is cardiovascular disorder.